AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions of the claims and listing of the claims in the application:

What is claimed is:

1. (Withdrawn) A method of treating a patient suffering from or susceptible to an RSV infection, which method comprises administering to said patient an effective amount of a benzodiazepine derivative of formula (I), or a pharmaceutically acceptable salt thereof,



(I)

wherein:

- R^1 represents C_{1-6} alkyl, aryl or heteroaryl;
- R^2 represents hydrogen or C_{1-6} alkyl;
- each R^3 is the same or different and represents halogen, hydroxy, C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} alkylthio, C_{1-6} haloalkyl, C_{1-6} haloalkoxy, amino, mono(C_{1-6} alkyl)amino, di(C_{1-6} alkyl)amino, nitro, cyano, $-CO_2R'$, $-CONR'R''$, $-NH-CO-R'$, $-S(O)R'$, $-S(O)_2R'$, $-NH-S(O)_2R'$, $-S(O)NR'R''$ or $-S(O)_2NR'R''$, wherein each R' and R'' is the same or different and represents hydrogen or C_{1-6} alkyl;
- n is from 0 to 3;
- R^4 represents hydrogen or C_{1-6} alkyl;
- R^5 represents C_{1-6} alkyl, aryl, heteroaryl, carbocyclyl, heterocyclyl, aryl-(C_{1-6} alkyl)-, heteroaryl-(C_{1-6} alkyl)-, carbocyclyl-(C_{1-6} alkyl)-, heterocyclyl-(C_{1-6} alkyl)-, aryl-(C_{1-6} hydroxyalkyl)-, heteroaryl-(C_{1-6} hydroxyalkyl)-, carbocyclyl-(C_{1-6} hydroxyalkyl)-, heterocyclyl-(C_{1-6} hydroxyalkyl)-, aryl-C(O)-C(O)-, heteroaryl-C(O)-C(O)-, carbocyclyl-C(O)-C(O)-, heterocyclyl-C(O)-C(O)- or $-XR^6$;
- X represents -CO-, -S(O)- or $-S(O)_2-$; and
- R^6 represents C_{1-6} alkyl, hydroxy, C_{1-6} alkoxy, C_{1-6} alkylthio, aryl, heteroaryl, carbocyclyl, heterocyclyl, aryl-(C_{1-6} alkyl)-, heteroaryl-(C_{1-6} alkyl)-, carbocyclyl-(C_{1-6}

alkyl)-, heterocyclyl-(C_{1-6} alkyl)-, aryl-(C_{1-6} alkyl)-O-, heteroaryl-(C_{1-6} alkyl)-O-, carbocyclyl-(C_{1-6} alkyl)-O-, heterocyclyl-(C_{1-6} alkyl)-O- or -$NR'R''$ wherein each R' and R'' is the same or different and represents hydrogen, C_{1-6} alkyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, aryl-(C_{1-6} alkyl)-, heteroaryl-(C_{1-6} alkyl)-, carbocyclyl-(C_{1-6} alkyl)- or heterocyclyl-(C_{1-6} alkyl)-.

2. (Withdrawn) A method according to claim 1 wherein:

- each R^3 is the same or different and represents halogen, hydroxy, C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} alkylthio, C_{1-6} haloalkyl, C_{1-6} haloalkoxy, amino, mono(C_{1-6} alkyl)amino, di(C_{1-6} alkyl)amino, nitro, cyano, -CO_2R', -$CONR'R''$, -NH-CO-R', -$S(O)R'$, -$S(O)_2R'$, -NH-$S(O)_2R'$ or -$S(O)NR'R''$, wherein each R' and R'' is the same or different and represents hydrogen or C_{1-6} alkyl;
- R^5 represents C_{1-6} alkyl, aryl, heteroaryl, carbocyclyl, heterocyclyl, aryl-(C_{1-6} alkyl)-, heteroaryl-(C_{1-6} alkyl)-, carbocyclyl-(C_{1-6} alkyl)-, heterocyclyl-(C_{1-6} alkyl)- or -XR^6;
- X represents -CO-, -S(O)- or -$S(O)_2$-; and
- R^6 represents C_{1-6} alkyl, hydroxy, C_{1-6} alkoxy, C_{1-6} alkylthio, aryl, heteroaryl, carbocyclyl, heterocyclyl, aryl-(C_{1-6} alkyl)-, heteroaryl-(C_{1-6} alkyl)-, carbocyclyl-(C_{1-6} alkyl)-, heterocyclyl-(C_{1-6} alkyl)- or -$NR'R''$ wherein each R' and R'' is the same or different and represents hydrogen, C_{1-6} alkyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, aryl-(C_{1-6} alkyl)- or heteroaryl-(C_{1-6} alkyl)-.

3. (Withdrawn) A method according to claim 1, wherein R^1 is C_{1-2} alkyl or aryl.

4. (Withdrawn) A method according to claim 1, wherein R^2 is hydrogen.

5. (Withdrawn) A method according to claim 1, wherein R^3 is halogen, hydroxy, C_{1-4} alkyl, C_{1-4} alkoxy, C_{1-4} alkylthio, C_{1-4} haloalkyl, C_{1-4} haloalkoxy, amino, mono(C_{1-4} alkyl)amino or di(C_{1-4} alkyl)amino.

6. (Withdrawn) A method according to claim 5, wherein R^3 is fluorine, chlorine, bromine, C_{1-2} alkyl, C_{1-2} alkoxy, C_{1-2} alkylthio, C_{1-2} haloalkyl, C_{1-2} haloalkoxy, amino, mono(C_{1-2} alkyl)amino or di (C_{1-2} alkyl)amino.

7. (Withdrawn) A method according to claim 1, wherein R^4 is hydrogen or C_{1-2} alkyl.

8. (Withdrawn) A method according to claim 1, wherein R^5 is C_{1-6} alkyl, aryl, heteroaryl, carbocyclyl, heterocyclyl, aryl-(C_{1-4} alkyl)-, heteroaryl-(C_{1-4} alkyl)-, carbocyclyl-(C_{1-4} alkyl)-, heterocyclyl-(C_{1-4} alkyl)-, aryl-C(O)-C(O)-, heteroaryl-C(O)-C(O)- or -XR^6.

9. (Withdrawn) A method according to claim 8, wherein R^5 is C_{1-4} alkyl, aryl, heteroaryl, carbocyclyl, heterocyclyl, phenyl-(C_{1-2} alkyl)-, heteroaryl-(C_{1-2} alkyl)-, phenyl-C(O)-C(O)-, heteroaryl-C(O)-C(O)- or -XR^6.

10. (Withdrawn) A method according to claim 9, wherein R^5 is C_{1-4} alkyl, phenyl, thienyl, furanyl, isoxazolyl, pyridyl, cyclopentyl, cyclohexyl, benzothienyl, dihydrobenzofuranyl, phenyl-CH_2-, furanyl-CH_2-, phenyl-C(O)-C(O)-, thienyl-C(O)-C(O)- or -XR^6.

11. (Withdrawn) A method according to claim 1 wherein X is -CO- or -$S(O)_2$-.

12. (Withdrawn) A method according to claim 1 wherein, when R^6 is a group -$NR'R''$ wherein each R' and R'' is the same or different and represents hydrogen, C_{1-4} alkyl, aryl, carbocyclyl, heterocyclyl, aryl-(C_{1-4} alkyl)- or heteroaryl-(C_{1-4} alkyl)-.

13. (Withdrawn) A method according to claim 12, wherein when R^6 is a group -$NR'R''$ each R' and R'' is the same or different and represents hydrogen, C_{1-4} alkyl, phenyl, thienyl, cyclohexyl, cyclopentyl or phenyl-CH_2-.

14. (Withdrawn) A method according to claim 13, wherein when R^6 is a group -$NR'R''$ and one of R' and R'' is hydrogen.

15. (Withdrawn) A method according to claim 1 wherein R^6 is C_{1-6} alkyl, hydroxy, C_{1-6} alkoxy, C_{1-6} alkylthio, aryl, heteroaryl, carbocyclyl, heterocyclyl, aryl-(C_{1-4} alkyl)-, heteroaryl-(C_{1-4} alkyl)-, carbocyclyl-(C_{1-4} alkyl)-, heterocyclyl-(C_{1-4} alkyl)-, aryl-(C_{1-4} hydroxyalkyl)-, heteroaryl-(C_{1-4} hydroxyalkyl)-, carbocyclyl-(C_{1-4} hydroxyalkyl)-, heterocyclyl-(C_{1-4} hydroxyalkyl)-, aryl-(C_{1-4} alkyl)-O-, heteroaryl-(C_{1-4} alkyl)-O-, carbocyclyl-(C_{1-4} alkyl)-O-, heterocyclyl-(C_{1-4} alkyl)-O- or -$NR'R''$.

16. (Withdrawn) A method according to claim 15, wherein R^6 is C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} alkylthio, aryl, heteroaryl, carbocyclyl, heterocycly, phenyl-(C_{1-2} alkyl)-, phenyl-(C_{1-2} alkyl)-O-, heteroaryl-(C_{1-2} alkyl)-, phenyl-(C_{1-2} hydroxyalkyl)-, heteroaryl-(C_{1-2} hydroxyalkyl)- or -$NR'R''$.

17. (Withdrawn) A method according to claim 16, wherein R^6 is C_{1-4} alkyl, C_{1-4} alkoxy, phenyl, naphthyl, dihydrobenzofuranyl, benzodioxinyl, 9H-fluoren-9-onyl, indolyl, thienyl, furanyl, oxazolyl, isoxazolyl, pyrazolyl, pyridyl, benzothienyl, benzofuranyl, cyclopentyl, cyclohexyl, piperazinyl, piperidinyl, morpholinyl, phenyl-(C_{1-2} alkyl)-, phenyl-CH_2-CH(OH)-, phenyl-CH(OH)-CH_2-, phenyl-(C_{1-2} alkyl)-O-, 1*H*-benzo[*d*]imidazol-2(3*H*)-onyl or -$NR'R''$.

18. (Withdrawn) A method according to claim 1, wherein the benzodiazepine derivative of formula (I) is a benzodiazepine derivative of formula (Ia):



(Ia)

wherein:

- R^1 is phenyl or methyl;
- R^3 is methyl or chlorine;
- n is 0 or 1;
- R^4 is hydrogen or methyl;
- R^5 is phenyl-CH_2-, furanyl-CH_2-, thienyl-C(O)-C(O)- or -XR^6;
- X is -CO- or -$S(O)_2$-; and
- R^6 is C_{1-4} alkyl, C_{1-4} alkoxy, phenyl, naphthyl, dihydrobenzofuranyl, benzodioxinyl, 9H-fluoren-9-onyl, indolyl, thienyl, furanyl, oxazolyl, isoxazolyl, pyrazolyl, pyridyl, benzothienyl, benzofuranyl, cyclopentyl, cyclohexyl, piperazinyl, piperidinyl, morpholinyl, phenyl-(C_{1-2} alkyl)-, phenyl-CH_2-CH(OH)-, phenyl-CH(OH)-CH_2-, phenyl-(C_{1-2} alkyl)-O-, 1*H*-benzo[*d*]imidazol-2(3*H*)-onyl or -$NR'R''$ wherein each

R' and R'' is the same or different and represents hydrogen, C_{1-4} alkyl, phenyl, thienyl, cyclohexyl, cyclopentyl or phenyl-(CH_2)-,

the phenyl moiety in the group R^1 being unsubstituted or substituted by a single fluorine, chlorine, C_{1-2} alkyl, C_{1-2} alkoxy, C_{1-2} alkylthio, C_{1-2} haloalkyl or C_{1-2} haloalkoxy substituent;

the aryl moieties in the groups R^5 and R^6 being unsubstituted or substituted by 1,2 or 3 substituents selected from fluorine, chlorine, bromine, iodine, C_{1-4} alkyl, C_{2-4} acyl, hydroxy, C_{1-4} alkoxy, C_{1-4} alkylthio, C_{1-4} haloalkyl, C_{1-4} haloalkoxy, amino, mono(C_{1-4} alkyl)amino, di(C_{1-4} alkyl)amino, nitro, $-CO_2R'$, $-S(O)_2R'$ and $-S(O)_2NH_2$, wherein R' represents C_{1-2} alkyl;

the heteroaryl moieties in the groups R^5 and R^6 being unsubstituted or substituted by 1 or 2 substituents selected from fluorine, chlorine, bromine, C_{1-2} alkyl, C_{1-2} haloalkyl and di(C_{1-2} alkyl)amino; and

the heterocyclyl and carbocyclyl moieties in the R^6 group being unsubstituted or substituted by 1 or 2 substituents selected from fluorine, chlorine, bromine,C_{1-4} alkyl, C_{1-4} alkoxy, C_{1-4} haloalkyl and nitro.

19. (Withdrawn) A method according to claim 1, wherein the patient is a child under two years of age.

20. (Withdrawn) A method according to claim 19 wherein said child suffers from chronic lung disease.

21. (Withdrawn) A method according to claim 1 wherein the patient is an infant less than six years of age who was born after 32 weeks of gestation or less.

22. (Withdrawn) A method according to claim 1, wherein the benzodiazepine derivative or salt thereof is administered intranasally or intrabronchially.

23. (Withdrawn) A method according to claim 1, wherein an anti-inflammatory compound or an anti-influenza compound is further administered to the patient.

24. (Withdrawn) A method according to claim 23 wherein the anti-inflammatory compound is budesonide or fluticasone.

25. (Withdrawn) A method according to claim 23 wherein the anti-inflammatory compound is a leukotriene antagonist, phosphodiesterase 4 inhibitor or TNF alpha inhibitor.

26. (Withdrawn) A method according to claim 23 wherein the anti-inflammatory compound is an interleukin 8 or interleukin 9 inhibitor.

27-30. (Canceled)

31. (Withdrawn) An inhaler or nebuliser containing a medicament which comprises
(a) a benzodiazepine derivative of formula (I), as defined in claim 1, or a pharmaceutically acceptable salt thereof, and
(b) a pharmaceutically acceptable carrier or diluent.

32. (Withdrawn) A product comprising a compound of formula (I), or pharmaceutically acceptable salt thereof, as defined in claim 1, and an anti-inflammatory compound, or an anti-influenza compound.

33. (Withdrawn) A method of treating a patient suffering from or susceptible to concomitant RSV and influenza infections, which method comprises administering to said patient an effective amount of a product according to claim 32.

34. (Withdrawn) A method of treating a patient suffering from or susceptible to human metapneumovirus, measles, parainfluenza viruses, mumps, yellow fever virus (B5 strain), Dengue 2 virus or West Nile virus, which method comprises administering to said patient an effective amount of a compound of formula (I), as defined in claim 1, or a pharmaceutically acceptable salt thereof.

35-37. (Canceled)

38. (Currently amended) A compound of formula (Ic), or a pharmaceutically acceptable salt thereof,



(Ic)

wherein:

- R^1 is phenyl or methyl;
- R^3 is methyl or chlorine;
- n is 0 or 1;
- R^4 is hydrogen or methyl;
- $R^{5'}$ is ~~phenyl CH_2 thienyl C(O) C(O) or~~ -X';
- X' is ~~CO $R^{6'}$,~~ -CONR'R", ~~$S(O)_2R^{6''''}$ or $S(O)_2NR_/R_{//}$;~~ and

~~$R^{6'}$ is C_{1-4} alkoxy, benzodioxinyl, 9H fluoren 9 onyl, furanyl, oxazolyl, isoxazolyl, pyrazolyl, pyridyl, cyclopentyl, piperazinyl, piperidinyl, morpholinyl, phenyl CH_2 CH(OH) , phenyl CH(OH) CH_2 , phenyl (C_2 alkyl) O or 1*H* benzo[*d*]imidazol 2(3*H*) only;~~

~~$R^{6''''}$ is C_{1-4} alkyl, C_{1-4} alkoxy, phenyl, naphthyl, dihydrobenzofuranyl, benzodioxinyl, 9H fluoren 9 onyl, indolyl, thienyl, furanyl, oxazolyl, isoxazolyl, pyrazolyl, pyridyl, benzothienyl, benzofuranyl, cyclopentyl, cyclohexyl, piperazinyl, piperidinyl, morpholinyl, phenyl (C_{1-2} alkyl) , phenyl CH_2 CH(OH) , phenyl CH(OH) CH_2 , phenyl (C_{1-2} alkyl) O or 1*H* benzo[*d*]imidazol 2(3*H*) only;~~

- each $R^/$ and $R^{//}$ is the same or different and represents hydrogen, C_{1-4} alkyl, phenyl, thienyl, cyclohexyl, cyclopentyl or phenyl-(CH_2)-; and

~~each $R_/$ and $R_{//}$ is the same or different and represents hydrogen, C_{1-4} alkyl, phenyl, thienyl, cyclohexyl, cyclopentyl or phenyl (CH_2) ,~~ wherein:

the phenyl moiety in the group R^1 being unsubstituted or substituted by a single fluorine, chlorine, C_{1-2} alkyl, C_{1-2} alkoxy, C_{1-2} alkylthio, C_{1-2} haloalkyl or C_{1-2} haloalkoxy substituent;

~~the aryl moieties in the groups $R^{5'}$, $R^{6'}$ and $R^{6''''}$ being unsubstituted or substituted by 1,2 or 3 substituents selected from fluorine, chlorine, bromine, iodine, C_{1-4} alkyl, C_{2-4} acyl, hydroxy, C_{1-4} alkoxy, C_{1-4} alkylthio, C_{1-6} haloalkyl, C_{1-4} haloalkoxy, amino,~~

~~mono(C_{1-4}-alkyl)amino, di(C_{1-4}-alkyl)amino, nitro, $-CO_2R'$, $-S(O)_2R'$ and $-S(O)_2NH_2$, wherein R' represents C_{1-2}-alkyl;~~

~~the heteroaryl moieties in the groups $R^{5'}$, $R^{6'}$ and $R^{6'''}$ being unsubstituted or substituted by 1 or 2 substituents selected from fluorine, chlorine, bromine, C_{1-2}-alkyl, C_{1-2}-haloalkyl and di(C_{1-2}-alkyl)amino;~~

~~the heterocyclyl and carbocyclyl moieties in the $R^{6'''}$ group being unsubstituted or substituted by 1 or 2 substituents selected from fluorine, chlorine, bromine, C_{1-4}-alkyl, C_{1-4}-alkoxy, C_{1-4}-haloalkyl and nitro;~~

the phenyl, thienyl, cyclohexyl, cyclopentyl or phenyl-(CH_2)- ~~aryl, heteroaryl and carbocyclyl~~ moieties in the R' and R'' being unsubstituted or substituted by one or two substituents selected from fluorine, chlorine, bromine, C_{1-2} alkyl, C_{1-2} alkoxy, C_{1-2} alkylthio, C_{1-2} haloalkyl and nitro~~; and~~

~~the aryl, heteroaryl and carbocyclyl moieties in the $R_{/}$ and $R_{//}$ being unsubstituted or substituted by one or two substituents selected from fluorine, chlorine, bromine, C_{1-2} alkyl, C_{1-2}-alkoxy, C_{1-2}-alkylthio, C_{1-2}-haloalkyl and nitro,~~
~~provided that the compound of formula (Ie) is N-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-acetamide~~.

39. (Canceled)

40. (Currently amended) A compound of formula (Ie) or [[a]] pharmaceutically acceptable salts thereof



(Ie)

wherein R'* is an aryl group which is unsubstituted or substituted by 1 or 2 substituents selected from fluorine, chlorine, bromine, C_{1-4} alkyl, C_{1-4} alkylthio, C_{1-4} haloalkyl, C_{1-4} haloalkoxy and nitro.

41. (Currently amended) A compound ~~according to claim 35,~~ selected from 1,1-Diethyl-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-urea;

~~Piperidine-1-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;~~

~~Morpholine-4-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;~~

~~4-Methyl-piperazine-1-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide~~;

~~Benzo[b]thiophene-3-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide~~;

~~Isoxazole-5-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide~~;

~~Benzo[b]thiophene-2-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide~~;

~~N-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-methanesulfonamide~~;

~~Propane-1-sulfonic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide~~;

~~Butane-1-sulfonic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide~~;

~~N-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-isonicotinamide~~;

~~N-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-nicotinamide~~;

~~(S)-2-Methoxy-4-nitro-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide~~;

(S)-1-(2-Fluoro-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-urea;

~~2-Chloro-4-methanesulfonyl-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide~~;

1-(4-Nitro-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-urea;

~~4-Methanesulfonyl-2-methoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide~~;

~~2-Methoxy-4-methylsulfanyl-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide~~;

~~4 Methanesulfonyl N (2 oxo 5 phenyl 2,3 dihydro 1H benzo[e][1,4]diazepin 3 yl) benzamide~~;

~~N (2 Oxo 5 phenyl 2,3 dihydro 1H benzo[e][1,4]diazepin 3 yl)terephthalamic acid methyl ester~~;

~~5 Acetyl 2 ethoxy N (2 oxo 5 phenyl 2,3 dihydro 1H benzo[e][1,4]diazepin 3 yl) benzamide~~;

~~3 Methoxy N (2 oxo 5 phenyl 2,3 dihydro 1H benzo[e][1,4]diazepin 3 yl) terephthalamic acid methyl ester~~;

~~2 Methylsulfanyl N (2 oxo 5 phenyl 2,3 dihydro 1H benzo[e][1,4]diazepin 3 yl) benzamide~~;

~~4 Amino 5 chloro 2 methoxy N (2 oxo 5 phenyl 2,3 dihydro 1H benzo[e][1,4]diazepin 3 yl) benzamide~~;

~~4 Methanesulfonyl 2 methoxy N (2 oxo 5 phenyl 2,3 dihydro 1H benzo[e][1,4]diazepin 3 yl) benzamide~~;

~~(S) 2,4,5 Trifluoro N (2 oxo 5 phenyl 2,3 dihydro 1H benzo[e][1,4]diazepin 3 yl) benzamide~~;

~~(S) 5 Acetyl 2 ethoxy N (2 oxo 5 phenyl 2,3 dihydro 1H benzo[e][1,4]diazepin 3 yl) benzamide~~;

~~2 Methoxy N (2 oxo 5 phenyl 2,3 dihydro 1H benzo[e][1,4]diazepin 3 yl) 5 sylfamoyl benzamide~~;

1-tert-Butyl-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-urea;

~~1 Cycloheyl 3 (2 oxo 5 phenyl 2,3 dihydro 1H benzo[e][1,4]diazepin 3 yl) urea~~

1-Cyclohexyl-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-urea;

1-Ethyl-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-urea;

1-Butyl-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-urea;

~~4,5 Dimethyl furan 2 carboxylic acid (2 oxo 5 phenyl 2,3 dihydro 1H benzo[e][1,4]diazepin 3 yl)amide~~;

~~Piperidine 1 carboxylic acid (7 chloro 2 oxo 5 phenyl 2,3 dihydro 1H benzo[e][1,4]diazepin 3 yl) amide~~;

~~Cyclohexanecarboxylic acid [5 (3 chloro phenyl) 2 oxo 5 phenyl 2,3 dihydro 1H benzo[e][1,4]diazepin 3 yl] amide;~~

~~Piperidine-1-carboxylic acid [5-(3-chloro-phenyl)-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-amide;~~

~~N-[5-(3-Chloro-phenyl)-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]isonicotinamide~~;

~~Cyclohexanecarboxylic acid [5-(3-methoxy-phenyl)-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-amide;~~

~~Piperidine-1-carboxylic acid [5-(3-methoxy-phenyl)-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-amide;~~

~~Piperidine-4-carboxylic acid [5-(3-methoxy-phenyl)-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-amide;~~

~~Cyclohexanecarboxylic acid (8-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide~~;

~~6-Morpholin-4-yl-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-nicotinamide~~;

~~Pyridine-2-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide~~;

~~6-Fluoro-4H-benzo[1,3]dioxine-8-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide~~;

~~1H-Pyrazole-4-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide~~;

~~6-Dimethylamino-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-nicotinamide~~;

~~2-Ethoxy-naphthalene-1-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide~~;

~~9-Oxo-9H-fluorene-1-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide~~;

~~2-Oxo-2,3-dihydro-benzoimidazole-1-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide~~;

~~(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)carbamic acid tert-butyl ester~~;

~~(S)-6-Fluoro-4H-benzo[1,3]dioxine-8-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide~~;

~~(S) 4,5 Dibromo furan 2 carboxylic acid (2 oxo 5 phenyl 2,3 dihydro 1H benzo[e][1,4]diazepin 3 yl) amide~~;
~~(S) 3 Methoxy naphthalene 2 carboxylic acid (2 oxo 5 phenyl 2,3 dihydro 1H benzo[e][1,4]diazepin 3 yl) amide~~;
~~(2 Oxo 5 phenyl 2,3 dihydro 1H benzo[e][1,4]diazepin 3 yl) carbamic acid methyl ester~~;
~~(2 Oxo 5 phenyl 2,3 dihydro 1H benzo[e][1,4]diazepin 3 yl) carbamic acid ethyl ester~~;
~~(2 Oxo 5 phenyl 2,3 dihydro 1H benzo[e][1,4]diazepin 3 yl) carbamic acid isobutyl ester~~; or
~~2 Oxo N (2 oxo 5 phenyl 2,3 dihydro 1H benzo[e][1,4]diazepin 3 yl) 2 thiophene 2 yl acetamide~~;
or a pharmaceutically acceptable salt thereof.

42. (Canceled)

43. (Withdrawn) A pharmaceutical composition comprising a benzodiazepine derivative according to Claim 31, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable diluant or carrier.

44. (Withdrawn) A composition comprising an optically active isomer of a benzodiazepine derivative according to Claim 31.

45. (Withdrawn) A composition according to claim 43 which is in the form of a tablet, troche, lozenge, aqueous or oily suspension, dispersible powders or granules.

46. (Withdrawn) A process for preparing a benzodiazepine derivative of the formula (I), as defined in claim 1, or a pharmaceutically acceptable salt thereof, which process comprises:

(a) reacting 2-amino-benzophenone with bromoacetyl bromide, or an equivalent reagent, followed by ring closure with ammonia;

(b) protecting the NH group on the thus obtained compound by reacting with a base and an alkylating agent;

(c) reacting the protected intermediate thereby obtained with a base in a suitable solvent, to obtain thereby an oxime intermediate;

(d) converting the thus obtained oxime intermediate into a corresponding racemic primary amine;

(e) carrying out dynamic kinetic resolution on the racemic amine in the presence of a suitable optically active acid and a suitable aldehyde to precipitate a salt of the (S)-amine.

47. (Withdrawn) A process according to claim 46, which further comprises:
(f) transforming the optically active amine obtained in step (e) into an amide or urea.

48. (Withdrawn) A process according to claim 46 wherein the protecting group introduced in step (b) is 4-methoxy-benzyl.

49. (Withdrawn) A process according to claim 46, wherein the benzodiazepine derivative of the formula (I) is (S)-1-(2-fluorophenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-urea or (S)-4-methanesulfonyl-2-methoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide.

50. (Previously presented) The compound of claim 40, wherein R'* is a phenyl group which is unsubstituted or substituted by a single fluorine, chlorine, or bromine substituent.

51. (Previously presented) A compound according to claim 40, wherein the compound is (S)-1-(2-Fluoro-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-urea.

52. (Canceled)

53. (New) A compound according to claim 40, wherein the compound is 1-(4-Nitro-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-urea.

54. (New) A compound according to claim 40, wherein the compound is 1-Butyl-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-urea.

55. (New) A compound according to claim 40, wherein the compound is 1,1-Diethyl-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-urea.

56. (New) A compound according to claim 40, wherein the compound is 1-tert-Butyl-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-urea.

57. (New) A compound according to claim 38, wherein R^1 is phenyl.